Trial Profile
Phase II trial of docetaxel plus imatinib mesylate in metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Imatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 15 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Dec 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 02 Apr 2008 The expected completion date for this trial is now May 2009 according to ClinicalTrials.gov